Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment

IF 22.5 1区 医学 Q1 ONCOLOGY
Nicholas P. Verdini, Karolina L. Bryl, Raymond E. Baser, Kaitlyn Lapen, Jun J. Mao, Erin F. Gillespie
{"title":"Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment","authors":"Nicholas P. Verdini, Karolina L. Bryl, Raymond E. Baser, Kaitlyn Lapen, Jun J. Mao, Erin F. Gillespie","doi":"10.1001/jamaoncol.2024.0280","DOIUrl":null,"url":null,"abstract":"ImportanceClinical trials are critical for progress in oncology; however, only 5% of the adult cancer population participates. Harnessing data that are routinely collected (ie, electronic patient-reported outcomes [ePROs]) may serve as a method to promote trial enrollment.ObjectiveTo evaluate if an ePRO-prompted recruitment strategy is associated with increased clinical trial enrollment.Design, Setting, and ParticipantsA randomized substudy was conducted from September 2022 to March 2023 at a multisite tertiary cancer center as part of an ongoing clinical trial that was testing a symptom-intervention for cancer-related fatigue. Patients with breast cancer who were undergoing radiotherapy who completed at least 1 ePRO questionnaire during the study period were included. Physician-level cluster randomization assigned fatigue-eligible patients to either receive a portal message invitation to a symptom-intervention trial or standard of care (SOC; physician-based referral).ExposureePRO questionnaires distributed in routine practice were queried weekly and screened for moderate or greater fatigue, the principle inclusion criterion for the primary trial. To assess the association of the portal message source with response and enrollment, every other patient received a message from the primary radiation oncology team or the referral service.Main Outcomes and MeasuresClinical trial response/referral and enrollment.ResultsA total of 1041 patients completed ePRO questionnaires, of whom 394 (38%; 53 Asian [13.6%], 43 Black [11.0%], 29 Hispanic [7.4%], and 262 White individuals [66.5%]; median [IQR] age, 55 [47-65] years) endorsed moderate or greater fatigue while receiving treatment. A total of 210 patients (53.3%) were assigned to receive a portal message and 184 (46.7%) patients, SOC. In the portal message group, 73 patients (35%) responded and 41 (20%) enrolled compared with 1 patient (0.5%) referred and 0 enrolled in the SOC group (<jats:italic>P</jats:italic> &amp;amp;lt; .001). The response rate to portal messages favored the referral service vs the primary radiation oncology service (44% vs 26%; <jats:italic>P</jats:italic> = .01), but there was no significant difference in enrollments.Conclusions and RelevanceThe study results suggest that use of routine care ePROs was associated with greater enrollment in a symptom-intervention trial compared with physician-based referral. Messaging directly from the referral service may support enrollment and help reduce oncology physician-level barriers to trial enrollment for studies testing symptom interventions.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"33 1","pages":""},"PeriodicalIF":22.5000,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaoncol.2024.0280","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

ImportanceClinical trials are critical for progress in oncology; however, only 5% of the adult cancer population participates. Harnessing data that are routinely collected (ie, electronic patient-reported outcomes [ePROs]) may serve as a method to promote trial enrollment.ObjectiveTo evaluate if an ePRO-prompted recruitment strategy is associated with increased clinical trial enrollment.Design, Setting, and ParticipantsA randomized substudy was conducted from September 2022 to March 2023 at a multisite tertiary cancer center as part of an ongoing clinical trial that was testing a symptom-intervention for cancer-related fatigue. Patients with breast cancer who were undergoing radiotherapy who completed at least 1 ePRO questionnaire during the study period were included. Physician-level cluster randomization assigned fatigue-eligible patients to either receive a portal message invitation to a symptom-intervention trial or standard of care (SOC; physician-based referral).ExposureePRO questionnaires distributed in routine practice were queried weekly and screened for moderate or greater fatigue, the principle inclusion criterion for the primary trial. To assess the association of the portal message source with response and enrollment, every other patient received a message from the primary radiation oncology team or the referral service.Main Outcomes and MeasuresClinical trial response/referral and enrollment.ResultsA total of 1041 patients completed ePRO questionnaires, of whom 394 (38%; 53 Asian [13.6%], 43 Black [11.0%], 29 Hispanic [7.4%], and 262 White individuals [66.5%]; median [IQR] age, 55 [47-65] years) endorsed moderate or greater fatigue while receiving treatment. A total of 210 patients (53.3%) were assigned to receive a portal message and 184 (46.7%) patients, SOC. In the portal message group, 73 patients (35%) responded and 41 (20%) enrolled compared with 1 patient (0.5%) referred and 0 enrolled in the SOC group (P &amp;lt; .001). The response rate to portal messages favored the referral service vs the primary radiation oncology service (44% vs 26%; P = .01), but there was no significant difference in enrollments.Conclusions and RelevanceThe study results suggest that use of routine care ePROs was associated with greater enrollment in a symptom-intervention trial compared with physician-based referral. Messaging directly from the referral service may support enrollment and help reduce oncology physician-level barriers to trial enrollment for studies testing symptom interventions.
将患者报告结果作为临床试验注册的一种招募策略
重要性临床试验对肿瘤学的发展至关重要;然而,只有5%的成年癌症患者参与了临床试验。利用常规收集的数据(即电子患者报告结果 [ePRO])可作为促进试验入组的一种方法。目标评估电子患者报告结果提示的招募策略是否与临床试验入组人数的增加有关。设计、设置和参与者2022年9月至2023年3月,在一家多地点三级癌症中心进行了一项随机子研究,作为正在进行的临床试验的一部分,该试验正在测试一种针对癌症相关疲劳的症状干预措施。研究对象包括正在接受放疗的乳腺癌患者,这些患者在研究期间至少填写了一份 ePRO 问卷。在常规治疗中发放的暴露ePRO问卷每周都会被查询并筛查出中度或更严重的疲劳,这也是主要试验的主要纳入标准。为了评估门户网站信息来源与响应和注册的关联性,每一位其他患者都收到了来自初级放射肿瘤团队或转诊服务机构的信息。主要结果和测量指标临床试验响应/转诊和注册。结果共有 1041 名患者完成了 ePRO 问卷调查,其中 394 名患者(38%;53 名亚裔[13.6%]、43 名黑人[11.0%]、29 名西班牙裔[7.4%]和 262 名白人[66.5%];中位[IQR]年龄 55 [47-65] 岁)在接受治疗期间表示有中度或更严重的疲劳感。共有 210 名患者(53.3%)被指定接受门户信息,184 名患者(46.7%)被指定接受 SOC。在门户网站信息组中,73 名患者(35%)做出了回应,41 名患者(20%)加入了该组,而在 SOC 组中,1 名患者(0.5%)被转介,0 名患者加入了该组(P &amp;lt; .001)。对门户网站信息的回复率有利于转诊服务,而不利于肿瘤放射学初级服务(44% vs 26%; P = .01),但注册人数没有显著差异。研究结果表明,与医生转诊相比,使用常规护理 ePRO 与更多人加入症状干预试验有关。转诊服务直接发送的信息可能会支持试验入组,并有助于减少肿瘤医生层面对症状干预试验入组的障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JAMA Oncology
JAMA Oncology Medicine-Oncology
自引率
1.80%
发文量
423
期刊介绍: JAMA Oncology is an international peer-reviewed journal that serves as the leading publication for scientists, clinicians, and trainees working in the field of oncology. It is part of the JAMA Network, a collection of peer-reviewed medical and specialty publications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信